ストックスクリーナーアプリを入手
23.02
5.46%
-1.33
アフターアワーズ：
23.02
前日終値:
$24.35
開ける：
$24.34
24時間の取引高:
1.23M
Relative Volume:
0.66
時価総額：
$3.65B
収益：
$1.27M
当期純損益:
$-508.02M
株価収益率:
-7.9911
EPS:
-2.8807
ネットキャッシュフロー:
$-419.23M
1週間 パフォーマンス:
-0.39%
1か月 パフォーマンス:
-10.50%
6か月 パフォーマンス:
+5.89%
1年 パフォーマンス:
+66.45%
1日の値動き範囲:
$22.99
$24.35
1週間の範囲:
$22.99
$24.68
52週間の値動き範囲:
$12.58
$27.30
Denali Therapeutics Inc Stock (DNLI) Company Profile
名前
Denali Therapeutics Inc
セクター
電話
(650) 866-8547
住所
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
23.02 | 3.74B | 1.27M | -508.02M | -419.23M | -2.8807 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2026-02-24 | 開始されました | Wolfe Research | Peer Perform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-04-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 再開されました | Morgan Stanley | Overweight |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2025-01-07 | 開始されました | Robert W. Baird | Outperform |
| 2025-01-03 | 開始されました | William Blair | Outperform |
| 2024-12-16 | アップグレード | Stifel | Hold → Buy |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-10-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 開始されました | B. Riley Securities | Buy |
| 2023-01-30 | 開始されました | SVB Securities | Outperform |
| 2022-12-05 | 開始されました | Cowen | Outperform |
| 2022-11-02 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-11-02 | 開始されました | BofA Securities | Buy |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-09-21 | 開始されました | Oppenheimer | Outperform |
| 2021-09-01 | 開始されました | SMBC Nikko | Outperform |
| 2021-05-18 | 開始されました | UBS | Buy |
| 2021-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-16 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-08-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-13 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-02-28 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-02-24 | 開始されました | Jefferies | Buy |
| 2020-02-19 | 開始されました | Stifel | Hold |
| 2020-01-27 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-26 | 開始されました | Wedbush | Neutral |
| 2019-09-13 | 開始されました | Nomura | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 開始されました | Janney | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 開始されました | Evercore ISI | Outperform |
| 2018-01-02 | 開始されました | Goldman | Neutral |
| 2018-01-02 | 開始されました | JP Morgan | Overweight |
| 2018-01-02 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Denali Therapeutics Inc (DNLI) 最新ニュース
Denali Therapeutics sells priority review voucher for $195 million gross proceeds - Bitget
Denali Therapeutics Inc (DNLI) Cash Flow - TradingKey
Denali sets Aug. 6 webcast on medicines crossing the blood-brain barrier - Stock Titan
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026 - marketscreener.com
Denali Therapeutics Inc (DNLI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Denali Therapeutics Inc (DNLI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Denali Therapeutics Inc (DNLI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Denali Therapeutics Inc (DNLI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Denali Therapeutics Inc (DNLI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
DNLI|Denali Therapeutics Inc|Price:23.570|Chg%:+0.460 - TradingKey
Denali Therapeutics Inc. Revenue Breakdown – NASDAQ:DNLI - TradingView
Denali Therapeutics Inc (DNLI) Institutional Confidence - TradingKey
DNLI Maintained by Morgan Stanley -- Price Target Raised to $36 - GuruFocus
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $36 - Moomoo
Denali Therapeutics (DNLI) Stock May Trade At A 12% Premium Following AAIC 2026 Plenary News - Sahm
Denali Therapeutics (DNLI) Heads To AAIC, Is The Stock Already Pricey? - Yahoo Finance
Goldman Sachs Remains a Buy on Denali Therapeutics (DNLI) - The Globe and Mail
Denali Therapeutics stock trades steady as ALS program advances and cash position supports pipeline - Ad-hoc-news.de
Is Denali Therapeutics (DNLI) Overvalued After Its FDA Approval? - Yahoo Finance
🤔🤔🤔🤔🤔🤔🤔🤔 - Moomoo
Denali Therapeutics (DNLI) Heads To Alzheimer’s Conference As Valuation Questions Return - Sahm
Trading Systems Reacting to (DNLI) Volatility - Stock Traders Daily
Deutsche Bank Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $35 - Moomoo
DENALI THERAPEUTICS INC. : DEUTSCHE BANK RAISES TARGET PRICE TO $35 FROM $31 - Bitget
Analysts’ Top Healthcare Picks: Denali Therapeutics (DNLI), Celcuity (CELC) - The Globe and Mail
Deutsche Bank Adjusts Price Target on Denali Therapeutics to $35 From $31, Maintains Buy Rating - marketscreener.com
Will Recent Setbacks Impact Growth Prospects of DNLI Stock? - Yahoo Finance
BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $31 - Moomoo
Jefferies Keeps Their Buy Rating on Denali Therapeutics (DNLI) - The Globe and Mail
Denali Therapeutics (DNLI) Faces 12.4% Decline in Share Value - GuruFocus
Denali Therapeutics Price Target Announced at $29.00/Share by JP Morgan - Moomoo
Wedbush Raises Price Target on Denali Therapeutics to $26 From $20, Keeps Outperform Rating - Moomoo
Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $26 - Moomoo
Denali Therapeutics (DNLI) Secures Overweight Rating from JPMorg - GuruFocus
JPMorgan resumes Denali Therapeutics stock coverage with Overweight rating By Investing.com - Investing.com Nigeria
BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial - Stocktwits
JPMorgan resumes Denali Therapeutics stock coverage with Overweight rating - Investing.com
H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's? -- Barrons.com - Moomoo
Denali Therapeutics (DNLI) Investor Day 2025 Summary - Quartr
T. Rowe Price’s 10% Stake and Avlayah Approval Could Be A Game Changer For Denali Therapeutics (DNLI) - Sahm
Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier - The Manila Times
Denali CEO to keynote AAIC 2026, highlighting a... - Pluang
Denali CEO to open AAIC 2026 with brain-delivery plan for Alzheimer’s - Stock Titan
Denali Therapeutics stock hits 52-week high at $26.95 By Investing.com - Investing.com South Africa
Denali Therapeutics stock hits 52-week high at $26.95 - Investing.com
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth? - Yahoo Finance
T. Rowe Price holds 10.2% of Denali Therapeutics (DNLI) in 13G/A - Stock Titan
Amyotrophic Lateral Sclerosis Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma - Barchart.com
DNLIDenali Therapeutics Inc Volatility & Greeks - Finviz
Denali Therapeutics (DNLI) Looks Fully Valued Following Its 32% 30 Day Rally - Sahm
Denali Therapeutics Inc (DNLI) 財務データ
収益
当期純利益
現金流量
EPS
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):